Journal ArticleOPEN ACCESS

Umbralisib plus ublituximab is superior to obinutuzumab plus chlorambucil in patients with treatment-naive and relapsed/refractory chronic lymphocytic leukemia: Results from the phase 3 unity-cll study

Clinical Advances in Hematology and Oncology (2021) 19(3) 8-9
DOI: 10.1182/blood-2020-134783
2Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Barr, P. M. (2021). Umbralisib plus ublituximab is superior to obinutuzumab plus chlorambucil in patients with treatment-naive and relapsed/refractory chronic lymphocytic leukemia: Results from the phase 3 unity-cll study. Clinical Advances in Hematology and Oncology, 19(3), 8–9. https://doi.org/10.1182/blood-2020-134783

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free